CAM
JAZZ icon

Cormorant Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Cormorant Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-100,000
Closed -$16.1M – 74
2014
Q3 		$16.1M Hold
100,000
– – 3.3% 3
2014
Q2 		$14.7M Hold
100,000
– – 3.9% 8
2014
Q1 		$13.9M Buy
+100,000
New +$15.1M 3.19% 11

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cormorant Asset Management's JAZZ Position: Q4 2014 in Review

Cormorant Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2014, closing a stake of 100,000 shares — an estimated $16.1M sold.

Cormorant Asset Management first reported a position in JAZZ in Q1 2014 and held it in 3 quarters. The position peaked at $16.1M in Q3 2014. 357 funds tracked by Wall St. Rank hold JAZZ as of Q4 2014.

  • Cormorant Asset Management reported no remaining Jazz Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Cormorant Asset Management sold 100,000 Jazz Pharmaceuticals shares in Q4 2014, an estimated $16.1M.
  • Cormorant Asset Management first reported a position in Jazz Pharmaceuticals in Q1 2014 and held it in 3 quarters.
  • Cormorant Asset Management's Jazz Pharmaceuticals position peaked at $16.1M in Q3 2014.
  • 357 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2014.

Based on Cormorant Asset Management's 13F filing for Q4 2014, filed 17 Feb 2015.